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Abstract
Background: The US Centers for Disease Control and Prevention (CDC) recently
add the advice of one-time testing of HCV infection in persons born during 1945–
1965. Moreover, the US Preventive Services Task Force (USPSTF) newly
recommended one-time HIV testing for persons aged 15–65. Herein, we evaluate the
potential impact of these recommendations in a reference medical area of Spain.
Methods: All assays results entries for HCV and HIV serological markers ordered
at a reference lab from primary care and specialized physicians between 2008 and
2012 were recorded in a medical area which covers 501,526 citizens in Northern
Spain. The year of birth were also documented.
Results: A total of 108,159 anti-HCV-Ab results were generated during the study
period. The global rate of anti-HCV-Ab+ was 7.7% (95% CI: 7.6%–7.9%), being
more prevalent in men than women (8.6% vs. 4.5%). By year of birth, the highest
prevalence was found in persons born between 1955 and 1970. HCV genotype 1
was the most prevalent (59.7%) followed by genotype 3 (22.7%). Regard HIV
infection, among 65,279 anti-HIV results generated the prevalence of anti-HIV+ was
1.1% (95% CI: 1.0%–1.2%), being more frequent in men (2% vs 0.5%). The years
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of birth with highest rates of HIV infection exactly match with those for HCV
infection.
Conclusions: The highest rates of HCV and HIV infections are found between
1960 and 1965. Different historical and social circumstances such as the huge
intravenous drug use epidemic in the eighties in Spain, might explain it. Therefore,
each country needs to determine its own HCV and HIV seroprevalences by year of
birth to establish the proper recommendations for the screening of both infections.
Introduction
Hepatitis C Virus infection (HCV) is considered a global public health problem
causing high rates of morbidity and mortality worldwide. The World Health
Organization (WHO) has estimated that around 2–3% of the world’s population
are infected with HCV which imply that 120–170 million people are HCV
chronically infected [1, 2].
Approximately 75–85% of acute HCV-infections progress to chronic liver
disease [3]. Since acute and chronic HCV infections are frequently asymptomatic,
patients frequently are unaware they are infected until very advanced stages of
their disease [4]. After 30 years of HCV infection, around 15%–30% of patients
develop cirrhosis and 1%–3% hepatocellular carcinoma (HCC), which is the
fastest growing cause of cancer-related mortality. Of note, HCV infection
accounts for approximately 50% of incident HCC [5]. Due to this latency, despite
HCV incidence has decreased in last decades, HCV-related mortality is increasing
annually. According to the Global Burden of Disease estimates, hepatitis B and
hepatitis C caused together 1.4 million deaths per year, including deaths from
acute infection, liver cancer and cirrhosis, very close to HIV infection (1.7 million
deaths/year) or tuberculosis (1.4 million deaths/year) in the worldwide [6]. In the
United States, HCV-associated mortality recently has exceeded the number of
deaths attributed to HIV [7]. A recent study carried in the United States estimated
that the mortality rate in HCV-infected persons is up to 12 times higher than that
found in the general population [8].
In 2012, the recommendation of Centers for Disease Control and Prevention
(CDC) expanded their recommendations for HCV testing with a birth-year-based
strategy. In 1998, CDC recommended routine HCV testing for high-risk
populations: exposure to injected illegal drugs, patients in hemodialysis or
recipients of organ transplants or transfusion previous to 1992, HIV+ patients,
clinical suspicion and persons with recognized exposure (Health Care workers and
children born to HCV+ women) [9]. National Health and Nutrition Examination
Survey (NHANES) data analysis estimated that the prevalence of HCV infection
was 5-fold greater in persons born during 1945 to 1965 (3.25%) than other adults;
this age group represents 76.5% of the total HCV-prevalence and 73% of HCV-
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related mortality in the United States [10, 11], thus CDC is now recommending
one-time HCV testing for persons born during these years [12].
HIV infection continues being an important public health problem. In Spain,
access to the health service is universal and free. It has been estimated that 72% of
people receive health care at least once a year [13]; but the late presenters are
about 40% of newly diagnoses patients [13], similar to other high-income
countries [14]. Two third of this late presenters had one or more contacts with the
health service previously, recognized as a missed opportunity for earlier HIV
diagnosis [15]. Screening strategies are critical to reduce the number of
undiagnosed persons and the proportion of late diagnoses in order to modify the
course of the epidemic. Recently, the US Preventive Services Task Force (USPSTF)
advised once HIV testing for persons aged 15–65 [16]; in 2010. Moreover, the
European Centre for Disease Control (ECDC), recommended the promotion of
strategies aimed at key populations at risk to enable early diagnosis of infection
[17].
In this context, the aim of this study was to assess the seroprevalence of HCV
and HIV infections by year of birth in our population to analyze the potential
impact of these recommendations in Northern Spain.
Methods
Study population
This cross-sectional study was carried out in Northern Spain (A Corun˜a
University Hospital), which covers a medical care area of 501.526 citizens. All
assays results entries for HCV and HIV serological markers ordered at our
laboratory from primary care and specialized physicians between 2008 and 2012
were recorded. Demographic data (sex and year of birth) and laboratory
parameters (anti-HCV, HCV genotype, HCV-RNA, anti-HIV, HIV-RNA and
CD4 count), considering the first determination after the positive serology result,
were also documented. All HIV/HCV coinfected patients followed in the same
area were also recorded for the analysis.
The study protocol was reviewed and approved by the Medical Ethics
Committee of the University Hospital of A Corun˜a. Publication of the study data
is in accordance with the community standards and approved by the ethics
committee. All patients data were anonymized and de-identified prior to analysis.
The identification numbers of patients were recoded blindly.
Serological tests
All serological tests were done with VITROS 3600 Immunodiagnostic System
(Ortho Clinical Diagnostics, Inc., a Johnson & Johnson company, NY, USA)
using: Anti-HIV 1+2 Reagent Pack, and Anti-HCV Reagent Pack, all of them
VITROS Immunodiagnostic Products. All patients with anti-HCV or anti-HIV
antibodies positive sera were retested using INNO-LIA HCV Score and INNO-
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LIA HIV I/II Score respectively by Auto-LIA 48 (Innogenetics N.V. Ghent,
Belgium) as complementary tests. Patients with both anti-HCV and LIA positive
reports were considered HCV positive. And patients with both anti-HIV and LIA
positive reports were considered HIV positive.
Plasma HCV-RNA was quantified using the real-time polymerase chain
reaction (RT-PCR) assay Cobas AmpliPrep/CobasTaqMan HCV
QuantitativeTest, version 2.0. (Roche Diagnostics. Ltd., in Rotkreuz, Switzerland)
with a lower limit of detection of 10 IU/mL. Plasma HIV-RNA was quantified
using the RT-PCR assay Cobas AmpliPrep/CobasTaqMan HIV-1 Test, version 2.0.
(Roche Diagnostics. Ltd., in Rotkreuz, Switzerland) with a lower limit of detection
of 20 copies/mL. HCV genotyping was measured with a commercial linear array
hepatitis C virus genotyping test and linear array detection kit (Roche Molecular
Systems, Inc. Branchburg, USA). All assays were performed according to the
manufacturer’s instructions.
Of note, to avoid an overestimation of both infections all duplicated HCV and
HIV tests for a same patient were identified and excluded for the analysis.
Statistical analyses
Anti-HCV+ and anti-HIV+ seroprevalences were calculated, according to year of
birth, together with their 95% confidence intervals (CI). Quantitative data were
expressed as mean (standard deviation) or median (interquartile range) and
analyzed with t-Student test. Qualitative data were expressed as percentage and
compared with chi-square test.
A time-trend joinpoint regression analysis was performed to analyze trends in
seroprevalence data according with year of birth. This technique provides the
estimated annual percent change (APC) and allows detecting points in time at
which significant changes in the trends occur. For each APC estimate, 95%
confidence interval was also calculated.
Results were considered statistically significant when p,0.05. Statistical
programs utilized were SPSS v16.0 for Windows (SPSS Inc.,Chicago,IL) and
Joinpoint Regression Program, version 3.4.2.
Results
1.- HCV infection
a) Seroprevalence of HCV infection
A total of 108,159 anti-HCV results were generated during the study period, the
mean age was 45.3¡18.0 years and 51.8% were male. The overall anti-HCV+ rate
were 7.7% (95% CI: 7.6%–7.9%). The yearly prevalence has remained stable
during the last 5 years: 9.1% (2008), 8.0% (2009), 7.3% (2010), 6.8% (2011), and
7.9% (2012).
Table 1 depicts the rates of anti-HCV+ by year of birth. In the joinpoint
regression analysis, three different trends were observed. Anti-HCV+ seropreva-
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lence remained stable among those born before 1955, followed by an increase
among those born between 1955 and 1970 (APC528.14%). A significant decrease
was documented for those born afterwards (APC5243.8%) (Table 2, Figure 1).
b) Clinical and microbiological characteristics of anti-HCV+ patients
Mean age on anti-HCV+ patients was 50.2¡16.6 years and 66.4% were male. The
HCV prevalence in men was 9.9% (95% CI: 9.7–10.2) and 5.4% (95% CI: 5.2–5.6)
(OR 1.9, 95%CI: 1.8–2.0; p,.001) in women; who were 10.8 years older than men
(57.4¡18.5 vs 46.6¡14.2; p,.001, 95%CI: 10.0–11.6).
From anti-HCV+ individuals, HCV-RNA was performed in 6442 (77%), a
mean of 44.2¡25.4 months after positive serology; of them, 56.3% (95% CI:
55.1%–57.5%) had detectable RNA-HCV, with a mean value of 5.7¡1.1 IU/mL.
HCV genotype was documented in 929 individuals, with the following
distribution: G1 59.7% (95% CI: 56.6%–62.9%), G2 5.4% (95% CI: 4.1%–7.0%),
Table 1. Seroprevalence of HCV and HIV infections, by year of birth, from 2008 to 2012.
Year of birth Tested for anti-HCV Ab Anti-HCV+ Tested for anti-HIV Ab Anti-HIV+
n n (%) 95% CI n n (%) 95% CI
Pre 1930 4131 334 (8.1) 7.2–8.9 1487 2 (0.1) 0.0–0.5
1931–1935 4306 388 (9) 8.1–9.9 1496 8 (0.5) 0.1–0.9
1936–1940 4294 369 (8.6) 7.7–9.4 1406 2 (0.1) 0–0.5
1941–1945 5498 362 (6.6) 5.9–7.2 1844 5 (0.3) 0.1–0.6
1946–1950 7839 630 (8) 7.4–8.6 2182 16 (0.7) 0.3–1.1
1951–1955 6652 411 (6.2) 5.6–6.8 2387 20 (0.8) 0.4–1.2
1956–1960 8361 795 (9.5) 8.8–10.1 3311 45 (1.4) 0.9–1.8
1961–1965 8881 1290 (14.5) 13.8–15.3 4027 122 (3) 2.5–3.6
1966–1970 11167 1513 (13.5) 12.9–14.2 6582 150 (2.3) 1.9–2.6
1971–1975 13113 1227 (9.4) 8.7–9.7 10654 129 (1.2) 1.0–1.4
1976–1980 13315 693 (5.2) 4.8–5.6 12665 124 (1) 0.8–1.1
1981–1985 9968 245 (2.5) 2.1–2.8 9031 78 (0.9) 0.7–1.1
1986–1990 5724 68 (1.2) 0.9–1.5 4759 25 (0.5) 0.3–0.7
Post 1990 4910 46 (0.9) 0.6–1.2 4170 20 (0.5) 0.2–0.7
TOTAL 108159 8371 (7.7) 7.6–7.9 65279 742 (1.1) 1.0–1.2
doi:10.1371/journal.pone.0113062.t001
Table 2. Joinpoint regression analysis: trends in HCV and HIV seroprevalence according to year of birth.
Period 1 Period 2 Period 3
Year of birth APC Year of birth APC Year of birth APC
Anti-HCV+ Pre
1930–1955






53.4 (26.5;85.9) 1965- Post
1990
227.1 (234.0;219.3) - -
APC5Annual percent change.
doi:10.1371/journal.pone.0113062.t002
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G3 22.7% (95% CI: 20.1%–25.5%), and G4 12.2% (95% CI: 10.2%–14.4%); more
than two-third had genotypes 1 or 4.
2.- HIV infection
a) Seroprevalence of HIV infection
A total of 65,279 anti-HIV tests were performed between 2008 and 2012. The
mean age of tested was 39.5¡16.1 years and 44% were male. The prevalence of
anti-HIV+ was 1.1% (95% CI: 1.0%–1.2%). The yearly rate has remained stable
during the study period: 1.1% (2008), 1.3% (2009), 1.4% (2010), 0.8% (2011),
1.0% (2012).
Similarly to HCV seroprevalence, the highest rates of anti-HIV+ Ab was
observed in the period between 1961–1965 (3%), followed by the period between
1966–1970 (2.3%) (Table 1). In this case, the joinpoint regression analysis
identified two different trends. Anti-HIV+ seroprevalence increased significantly
with year of birth for those born before 1965 (APC553.4%), decreasing
afterwards with an APC5227.1% (Table 2, Figure 1).
b) Clinical and microbiological characteristics of anti-HIV+ patients
The prevalence of anti-HIV+ in men was 2.0% (95% CI: 1.8–2.1) and in
women.5% (95% CI:.4–.6) (OR 4.1, 95%CI: 3.5–4.8; p,.001), mean age
39.5¡11.0, without difference between men (39.9¡10.7 years) and women
(38.5¡11.8 years) (95% CI 23.5–.7; p5.19).
Overall 742 were anti-HIV+, 310 (43%) were newly diagnosed. The mean age of
newly HIV diagnosed patients was 38.5¡11.3 years and 82% were men. The
median CD4 counts were 361 cels/ml (126–563) and the median HIV-RNA was 5
log cop/mL (4.4–5.5). The CD4 counts was analysed a mean of 3.9¡2.1 months
after positive HIV serology, and HIV-RNA a mean of 4.2¡2.2 months after. Of
them, 50.5% were late presenters (AIDS defining illness or,350 cells/ml total CD4
count). The prevalence of anti-HCV+ Ab in this subgroup of newly diagnosed was
13%.
A total of 1300 HIV infected patients were on clinical follow-up within the
study period in this medical area. The prevalence of HCV/HIV co-infection was
54%. Figure 2 illustrates the distribution by year of birth of this HCV/HIV co-
infected population.
Discussion
This study evaluates the seroprevalence of HCV and HIV infections by year of
birth in a medical reference area of Northern Spain between 2008 and 2012. The
overall seroprevalence of HCV infection during the study period was 7.7%. It is
Figure 1. Joinpoint regression analysis: trends in HCV and HIV seroprevalence according to year of birth.
doi:10.1371/journal.pone.0113062.g001
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significantly higher than previously reported in different studies in Spain in
general population and blood donors cohorts, with rates around 2.5–2.9%
[18, 19]. The higher prevalence we observed might be explained because our study
population includes patients with medical care requirements. Therefore, the HCV
screening ordered to our laboratory is derived from patients attending to primary
care clinics but also in clinical follow-up for hepatic disorders or previously
diagnosed for HCV and/or HIV infections at A Corun˜a University Hospital.
Moreover, HCV screening is also performed in patients attending at alcohol and
drug detox centers. In all these populations is well-known the higher rates of HCV
infection and consequently the seroprevalence of HCV infection is higher
compared to the general population [20, 21]. The prevalence on anti-HCV+ was
higher (OR 1.9) among men than in women and they were significantly younger.
These findings might be explained by the higher use of intravenous drugs in men
than in women.
The seroprevalence of HCV infection by year of birth highlights some
differences with that reported from the US. While in our study population we
found the highest seroprevalence of HCV infection in persons born during 1960–
1970 (14%) in the NHANES cohort, in the same period, they observed a
prevalence of 0.7%, more than three times lower. Therefore if a birth-year-based
HCV-screening strategy was implemented in our country, these data must be
considered to properly establish the optimal target population for HCV screening.
Considering the CDC recommendation, HCV testing for persons born between
1945 and 1965, only 37% (n53126) of the total anti-HCV+ subjects (n58371) in
our study population would be diagnosed [12]. Of the 63% hypothetical
undiagnosed patients, 72% of them would have been born after 1965, mainly
between 1965 and 1975, representing a younger group of patients in whom
monitoring and treatment options are more effective. Historical and social
circumstances might explain these differences including the huge intravenous
drug use epidemic occurred in the eighties in Spain, probably some years after
than in the US or other European countries. Regarding the virologic
characteristics of HCV infection, nearly of 60% of patients had detectable HCV-
RNA, half of them with high viral load (.6 log IU/mL) and more than two-third
had genotypes 1 or 4. This data has important clinical and therapeutics
implications since both genotypes are classically recognized such as the more
difficult to treat. HCV genotypes distribution in our study is similar to that
reported previously in the Spanish population [22]; in HCV/HIV coinfected we
found a slightly higher prevalence for genotypes 2 and 3 than in HCV
monoinfected, mainly associated with a higher proportion of intravenous drug
users in this population. The HCV genotypes distribution in Spain is quite
different than other European countries; of note, in Eastern Europe and UK the
prevalence of genotype 3 is up to 50%, and in Italy the prevalence of genotype 2 is
around 25% [18].
The new scenario for the treatment of HCV infection with new direct-acting
antiviral agents (DAA) allowing significantly higher rates of cure for all genotypes
and fairly or null adverse events, turns HCV diagnosis and treatment a cost-
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effective strategy [23]. However, in view of the results obtained in this study, each
country must assess the HCV seroprevalence by year of birth to establish the
optimal target population for HCV screening and to know its own HCV
prevalence distribution. These preliminary data suggest as target population for
HCV screening in Spain those persons born during 1955 and 1975.
The HIV seroprevalence was also evaluated since both infections share routes of
transmission. The prevalence of anti-HIV+ Ab was 1.1%, with a comparatively high
proportion of female’s tested (56%), consistent with recommendations for prenatal
HIV testing. However, the seroprevalence for HIV-infection is four times higher in
men than in women, according with data provided by the Spanish Public Health
authorities and the ECDC [24, 25]. Interestingly, the highest prevalence of HIV
infection by year of birth exactly matches with the peak of HCV prevalence,
recognized in persons born between 1955 and 1975. Moreover, these data support
the hypothesis that the differences in the HCV prevalence distribution by year of
birth in Spain compared with the US might be explained by the intravenous drug
use epidemic occurred in the eighties in our country. Of note, in the last years, the
main route of HIV transmission in our health area is sexually (more than 90% of
newly HIV-infected) [26], with a mean age of 38 years old. Consequently, the
prevalence of HIV infection is increasing in younger people. These data should be
considered for the implementation of appropiate HIV screening programs.
Since this is a retrospective study including the results obtained from HCV and
HIV screening in the last 5 years in our medical care area including high risk
populations, the figure of HCV prevalence might be overestimated. However, the
study has been conducted in a big sample (108,159 HCV tests, and 65,279 HIV
tests). Moreover, concordant results regarding the anti-HCV+, anti-HIV+ and
HCV/HIV co-infected prevalence distribution by year of birth support the
accuracy of these results.
In summary, the prevalence of HCV and HIV distribution varies by year of
birth in our population. The highest rates of HCV and HIV infection are observed
Figure 2. Distribution of the HCV/HIV co-infected patients (n5553) by year of birth.
doi:10.1371/journal.pone.0113062.g002
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in persons born between 1955–1975. The huge intravenous drug use epidemic
occurred in the eighties in Spain might explain these findings. Of note, regional
differences regard HIV and HCV prevalence and exposure groups have been
report from European cohorts [27, 28] providing important information for
future testing initiatives. Therefore, the recommendations made by the US CDC
of HCV testing among persons born in 1945–1965 once in a lifetime, might not be
applicable to other populations. For this reason, similarly to the US Health
Institutions, each country needs to determine its own HCV and HIV
seroprevalence by year of birth to identify its target population to implement the
appropriate screening programs. In Spain, once in a lifetime HCV testing might
be especially considered in persons aged 38–58. Regarding to HIV testing, due to
the high number of new HIV infections observed in younger persons, and
similarly to the USPSTF recommendations, once in a lifetime HIV testing might
be considered in persons aged 15–65 in Spain.
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